PRCT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Procept Biorobotics Corp (PRCT) is not a strong buy for a beginner, long-term investor at this moment. The stock faces significant headwinds, including disappointing Q4 results, lowered revenue guidance, and bearish technical indicators. While there are some positive aspects, such as insider buying and the potential for long-term growth in the medical robotics space, the lack of clear near-term catalysts and the bearish sentiment from analysts and hedge funds suggest holding off on investment for now.
The technical indicators are bearish. The stock's moving averages (SMA_200 > SMA_20 > SMA_5) indicate a downward trend. RSI is neutral at 39.457, and MACD is slightly positive but contracting. The stock is trading near its support level of 24.938, with resistance at 26.482, showing limited upward momentum.
Insider buying has increased significantly by 1235.17% over the last month, indicating confidence from company insiders.
The integration of AI in medical robotics is expected to revolutionize healthcare systems, which aligns with Procept's focus on minimally invasive therapies.
Hedge funds are selling, with a 465.92% increase in selling activity over the last quarter.
Analysts have lowered price targets significantly, and some have downgraded the stock to Neutral or Underperform.
The company lowered its 2025 revenue guidance and provided a 2026 revenue projection below expectations, raising concerns about its growth trajectory.
In Q4 2025, revenue grew by 11.94% YoY to $76.38M, but the company remains unprofitable with a net income of -$29.85M. EPS improved to -0.53, up 51.43% YoY, but gross margin dropped to 60.63%, down 5.27% YoY, indicating cost pressures.
Analysts have mixed ratings, with some maintaining Buy ratings but lowering price targets to $30 or below. Others have downgraded the stock to Neutral or Underperform, citing disappointing Q4 results, lowered guidance, and challenges in market penetration.
